KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 105 filers reported holding KEROS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $45,397 | -8.3% | 1,424 | +15.6% | 0.00% | 0.0% |
| Q2 2023 | $49,502 | +11.3% | 1,232 | +18.2% | 0.00% | 0.0% |
| Q1 2023 | $44,493 | -22.2% | 1,042 | -12.5% | 0.00% | -33.3% |
| Q4 2022 | $57,192 | +40.4% | 1,191 | +10.0% | 0.00% | +50.0% |
| Q3 2022 | $40,742 | +36.2% | 1,083 | 0.0% | 0.00% | +100.0% |
| Q2 2022 | $29,923 | -49.2% | 1,083 | 0.0% | 0.00% | -50.0% |
| Q1 2022 | $58,894 | -75.3% | 1,083 | -73.5% | 0.00% | -33.3% |
| Q4 2021 | $238,838 | +47.9% | 4,082 | 0.0% | 0.00% | +50.0% |
| Q3 2021 | $161,484 | -6.9% | 4,082 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $173,363 | -26.1% | 4,082 | +7.1% | 0.00% | -50.0% |
| Q1 2021 | $234,629 | -12.7% | 3,812 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $268,898 | +165.0% | 3,812 | +44.9% | 0.00% | +100.0% |
| Q3 2020 | $101,478 | +2.8% | 2,631 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $98,689 | – | 2,631 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 396,911 | $21,584,000 | 5.10% |
| Deep Track Capital, LP | 1,380,306 | $75,061,000 | 4.81% |
| Opaleye Management Inc. | 265,750 | $14,451,000 | 4.49% |
| Octagon Capital Advisors LP | 340,214 | $18,501,000 | 4.00% |
| First Light Asset Management, LLC | 658,145 | $35,790,000 | 3.16% |
| Altium Capital Management LP | 126,000 | $6,852,000 | 2.29% |
| Nantahala Capital Management | 816,830 | $44,419,000 | 1.96% |
| Orbimed Advisors | 1,679,417 | $91,327,000 | 1.48% |
| CHI Advisors LLC | 62,229 | $3,384,000 | 1.44% |
| Parkman Healthcare Partners LLC | 72,690 | $3,953,000 | 1.16% |